RT @weeloonong: Please join our esteemed international RO speakers in Melbourne in October for #RANZCR2025! Early bird registrations close….

N 90 patients with primary renal cell carcinoma. -Tumour Complexity: Most patients had moderately complex renal tumours (median R.E.N.A.L. nephrometry score of 9) with a median tumour size of 4.6 cm. Renal Function: The estimated glomerular filtration rate (eGFR) declined by.

Our article to look at the impact of tumour complexity on outcomes following SABR for primary kidney cancer.@_ShankarSiva @declangmurphy @PeterMacRadOnc @PeterMacCC .

Today, we achieved a small milestone of registering the 100th prospective patient at Peter MacCallum Cancer Centre. @_ShankarSiva @MellyB_7 @declangmurphy @PeterMacRadOnc @PeterMacCC .

Right atrial angiosarcoma not for surgery .5.5cm.What should be the radiotherapy dose/fraction? .@DrewMoghanaki @jryckman3 @_ShankarSiva.

RT @cristian_udo: Is there a role for PSMA PET/CT in oligometatastic RCC? .Check out our @JournalofNucMed PEDESTAL study on PSMA-guided met….

MRI awaited.

Early 60s man .Post RP 7 years ago .T3a, GS4+5 .Clear margin . PSA 0.7 .PET only avid site in the perineum at least 4 cm below VU junction .? RT .If yes what would be the dose/fraction .@DrAndrewLoblaw @SbrtSean @AmarUKishan @VedangMurthy

RT @DrewMoghanaki: A trio of radiation oncologists from France, the United States, and Australia asks why there is a desire to deliver SBRT….

Is it safe giving Lung SABR (oligoprogressive 1.5cm) to a patient on TDM1 for stage IV breast cancer? @DrewMoghanaki @drspdavid @_ShankarSiva @jryckman3.

Quick question to urology Rad Oncs.74 male, PSA 9.3, cT2a,26 core biopsy .- 3+3 in 5.-3+4 in 2 with 5% GS 4.-3+5 in 3 cores with 1% GS 5 (largest tumour focus 3mm).Will you offer ADT with RT? If yes any particular duration.@DrAndrewLoblaw @AmarUKishan @alison_tree @_ShankarSiva.

6/6; SABR was well tolerated without any G-3+ toxicity. The decline in GFR was acceptable (pre-SABR median 58 and post 48). Overall, these results suggest Salavage SABR as an option for this rare group of patients.

n/5: After a median follow-up of 3 + years, no RECIST defined local progression was experienced. However, one patient with persistent contrast following SABR underwent repeat TA.

n/4; SABR can be an attractive noninvasive salvage option for recurrent disease following TA. In this study, we reported outcomes for 17 patients with recurrent disease. Six patients had 2 or 3 procedures before SABR, where other modalities could be challenging.

n/3: Active surveillance is an otter option that can be considered in selective patients. However, recurrent disease can be aggressive and will not be ideal for AS.

n/2: Surgery is another salvage option. Partial nephrectomy is feasible but technically challenging due to post TA fibrosis. There is a risk of conversion to radical and grade 3/4 toxicity of 20-30%. (Small series varying 8-30 patients).

n/1: Short thread on management for recurrent disease following thermal ablation (TA).The recurrence rates are very low in carefully selected patients with small renal tumours (<3-4cm). Repeat TA can be an option but higher recurrence with repeat procedure, up to 50% with third.

Sharing our paper reporting the new indication of SABR for primary kidney cancer. @_ShankarSiva @AnnA25_03.

RT @drviviantan: and support of all collaborators! @dr_alimuhammad @AMuacevic @LPonsky @SimonLo21054188 @ASwaminathMD @dr_cury @MichaelStae….

Emerging Novel Functional Imaging and Immunotherapy in Renal Cell Carcinoma and Current Treatment Sequencing Strategies After Immunotherapy | American Society of Clinical Oncology Educational Book